Priority Review for Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate

 Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, as submitted for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

https://www.biospace.com/article/releases/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-pfizer-s-respiratory-syncytial-virus-vaccine-candidate-for-the-prevention-of-rsv-disease-in-older-adults/